Trade ADMA Biologics, Inc. - ADMA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.Latest shares articles

Buzzi stock forecast: H1 EBITDA and margin pressure
Buzzi is an Italian building-materials group listed in Milan, with recent trading shaped by a September share-price decline and a new investor presentation. Explore third-party BZU price targets and technical analysis. Past performance is not a reliable indicator of future results.
11:07, 25 September 2026

PKO BP stock forecast: POLSTR mortgages, KNF penalties
PKO Bank Polski introduced POLSTR 1M-linked mortgages from 3 September and is seeking reconsideration of five KNF penalties totalling 47.5m PLN. Explore third-party PKO price targets and technical analysis. Past performance is not a reliable indicator of future results.
11:40, 24 September 2026

Soitec stock forecast: €500m ORNANE bond
Soitec is a French semiconductor materials company. In September 2026, it placed €500m of 0.5% ORNANEs due in 2033, with settlement expected on 25 September. Explore third-party SOI price targets and technical analysis. Past performance is not a reliable indicator of future results.
10:51, 24 September 2026

Vossloh stock forecast: RTI acquisition expands digital rail
Vossloh is a German rail-infrastructure group that completed its acquisition of Rail Technology International on 15 September, expanding its digital inspection and analytics offering. Explore third-party VOS price targets. Past performance is not a reliable indicator of future results.
11:09, 23 September 2026